Details for Patent: 10,646,550
✉ Email this page to a colleague
Which drugs does patent 10,646,550 protect, and when does it expire?
Patent 10,646,550 protects VOXZOGO and is included in one NDA.
This patent has thirty-five patent family members in twenty-two countries.
Summary for Patent: 10,646,550
Title: | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Abstract: | The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component. |
Inventor(s): | Bullens; Sherry (Novato, CA), Bunting; Stuart (Novato, CA), Chou; Tianwei (Novato, CA), Okhamafe; Augustus O. (Concord, CA), Price; Christopher P. (Munich, DE), Wendt; Daniel J. (Novato, CA), Yap; Clarence (Novato, CA) |
Assignee: | BioMarin Pharmaceutical Inc. (Novato, CA) |
Application Number: | 15/880,002 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 10,646,550
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Sign Up | |||
Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-002 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Sign Up | |||
Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-003 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,646,550
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 105563 | ⤷ Sign Up | |||
Australia | 2016298425 | ⤷ Sign Up | |||
Australia | 2023200669 | ⤷ Sign Up | |||
Brazil | 112018001761 | ⤷ Sign Up | |||
Canada | 2994280 | ⤷ Sign Up | |||
Chile | 2018000215 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |